Neurology
-
Randomized Controlled Trial
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. ⋯ This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.
-
Randomized Controlled Trial
Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.
In this secondary analysis of the Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial, we report the effect of IV glyburide on adjudicated, edema-related endpoints. ⋯ This study provides Class II evidence that for patients with large hemispheric infarction, IV glyburide improves some edema-related endpoints.